

## \$100 billion of revenues up for grabs for drug manufacturers by 2020 as patents for key biologics expire

Écrit par GBI Research

Mardi, 14 Mars 2017 12:19 - Mis à jour Mardi, 14 Mars 2017 12:21

---



Although complexities inherent in biological drug manufacturing are creating barriers for further expansion

Adam Bradbury and Risk [Analyst](#) Mandilwar state that a new GBI Research analysis challenges the dominance of the top players

Mandilwar explains: “In order to be successful in the biosimilars sector, companies must adopt the latest

A number of biologics are set to go off patent before 2020, which presents a huge opportunity for biosimilar

Pricing for biosimilars is usually 30–50% lower than the innovator product. These cost advantages will

Bradbury concludes: “The biosimilar pipeline is robust, and most products are being developed for the